5.13
price up icon1.38%   0.07
after-market Dopo l'orario di chiusura: 5.16 0.03 +0.58%
loading
Precedente Chiudi:
$5.06
Aprire:
$5
Volume 24 ore:
37.94M
Relative Volume:
1.66
Capitalizzazione di mercato:
$2.22B
Reddito:
$64.60M
Utile/perdita netta:
$-377.75M
Rapporto P/E:
-3.3097
EPS:
-1.55
Flusso di cassa netto:
$-335.64M
1 W Prestazione:
-1.72%
1M Prestazione:
+22.73%
6M Prestazione:
-24.11%
1 anno Prestazione:
-31.23%
Intervallo 1D:
Value
$4.91
$5.44
Intervallo di 1 settimana:
Value
$4.91
$5.48
Portata 52W:
Value
$3.79
$12.36

Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile

Name
Nome
Recursion Pharmaceuticals Inc
Name
Telefono
(385) 269-0203
Name
Indirizzo
41S RIO GRANDE STREET, SALT LAKE CITY
Name
Dipendente
800
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-06
Name
Ultimi documenti SEC
Name
RXRX's Discussions on Twitter

Confronta RXRX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
RXRX
Recursion Pharmaceuticals Inc
5.13 2.22B 64.60M -377.75M -335.64M -1.55
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-05-22 Iniziato Morgan Stanley Equal-Weight
2023-03-16 Iniziato Needham Buy
2022-09-16 Iniziato KeyBanc Capital Markets Overweight
2022-04-18 Downgrade BofA Securities Buy → Neutral
2022-03-04 Downgrade SVB Leerink Outperform → Mkt Perform
2021-09-21 Iniziato Berenberg Buy
2021-05-11 Iniziato BofA Securities Buy
2021-05-11 Iniziato Goldman Neutral
2021-05-11 Iniziato JP Morgan Neutral
2021-05-11 Iniziato KeyBanc Capital Markets Overweight
2021-05-11 Iniziato SVB Leerink Outperform
Mostra tutto

Recursion Pharmaceuticals Inc Borsa (RXRX) Ultime notizie

pulisher
Jun 18, 2025

Recursion Pharmaceuticals stockholders elect three Class I directors - Investing.com Australia

Jun 18, 2025
pulisher
Jun 18, 2025

Recursion Pharmaceuticals stockholders elect three Class I directors By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 18, 2025

Recursion Pharmaceuticals Holds Annual Stockholder Meeting - TipRanks

Jun 18, 2025
pulisher
Jun 16, 2025

Expert Outlook: Recursion Pharmaceuticals Through The Eyes Of 4 Analysts - Benzinga

Jun 16, 2025
pulisher
Jun 16, 2025

Recursion Pharmaceuticals (RXRX): Morgan Stanley Adjusts Price Target | RXRX Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace

Jun 16, 2025
pulisher
Jun 16, 2025

Recursion Pharma to reduce workforce by 20% - MSN

Jun 16, 2025
pulisher
Jun 16, 2025

Why Recursion Pharmaceuticals Stock Is Plummeting Today - AOL.com

Jun 16, 2025
pulisher
Jun 16, 2025

Recursion Pharmaceuticals price target lowered to $5 by Morgan Stanley - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

Recursion Pharmaceuticals price target lowered to $5 from $8 at Morgan Stanley - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

Morgan Stanley Cuts Recursion Pharmaceuticals Price Target to $5 From $8, Maintains Equalweight Rating - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Is This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy? - MSN

Jun 16, 2025
pulisher
Jun 15, 2025

Why Recursion Pharmaceuticals RXRX Could Be the NVDA of Biotech for NASDAQ:RXRX by TopgOptions - TradingView

Jun 15, 2025
pulisher
Jun 14, 2025

Recursion to lay off 20% of workforce, narrows focus amid biotech downturn - MSN

Jun 14, 2025
pulisher
Jun 13, 2025

Recursion Q1 2025 slides: AI platform advances pipeline amid earnings miss By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Recursion Q1 2025 slides: AI platform advances pipeline amid earnings miss - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

Cautious Outlook on Recursion Pharmaceuticals Amid Strategic Restructuring and Cash Management Challenges - TipRanks

Jun 13, 2025
pulisher
Jun 11, 2025

Insmed surges on lung drug data; Recursion cuts staff - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today - MSN

Jun 11, 2025
pulisher
Jun 11, 2025

Recursion: Lack Of Near-Term Catalysts Leaves The Stock Vulnerable (NASDAQ:RXRX) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 10, 2025

Recursion Pharmaceuticals (RXRX) Jumps 31% On Next-Gen AI - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion to lay off 20% of workforce amid biotech funding woes - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Why Recursion Pharmaceuticals Was Bouncing Higher on Tuesday - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

After pipeline cull, AI drug developer Recursion cuts staff by 20% - FirstWord Pharma

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Eliminating 20% of Workforce, Citing Pipeline Pruning and Capital Markets - Genetic Engineering and Biotechnology News

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Pharmaceuticals Stock Surges After Company Lays Off 20% Workforce: Retail Predicts ‘Blue Skies’ Ahead - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Pharmaceuticals Stock Is Up 10% Today: What's Happening? - Benzinga

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Downsizes by 20% To Boost Cash Position - BioSpace

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion lays off 20% of staff in wake of pipeline cutbacks - Fierce Biotech

Jun 10, 2025
pulisher
Jun 10, 2025

Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Pharmaceuticals: Recent Readouts Disappointing, Future Readouts Risky (RXRX) - Seeking Alpha

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Cuts 20% of Workforce, Extends Cash Runway to Late 2027 - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Pharma to reduce workforce by 20% (RXRX:NASDAQ) - Seeking Alpha

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Pharmaceuticals Stock (RXRX): AI Breakthrough for Drug Development - Value The Markets

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Pharmaceuticals (RXRX) Implements Workforce and Operat - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Pharmaceuticals Announces Workforce Reduction Strategy - TipRanks

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Pharmaceuticals announces 20% workforce reduction - TipRanks

Jun 10, 2025
pulisher
Jun 10, 2025

Recursion Pharmaceuticals Announces Personnel And Infrastructure ReductionSEC Filing - marketscreener.com

Jun 10, 2025
pulisher
Jun 08, 2025

15 Stocks That Stole The Show Last Week - Insider Monkey

Jun 08, 2025
pulisher
Jun 07, 2025

Recursion rises on launch of Boltz-2 in partnership with MIT - MSN

Jun 07, 2025
pulisher
Jun 07, 2025

Why Recursion Pharmaceuticals (RXRX) Soared On Friday - Insider Monkey

Jun 07, 2025
pulisher
Jun 06, 2025

10 Stocks Are Dominating Like Wall Street Titans - Insider Monkey

Jun 06, 2025
pulisher
Jun 06, 2025

Recursion Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:RXRX - Benzinga

Jun 06, 2025
pulisher
Jun 06, 2025

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas - mx.advfn.com

Jun 06, 2025
pulisher
Jun 06, 2025

Recursion Pharmaceuticals Stock Surges On Breakthrough AI Model Launch With MIT - Benzinga

Jun 06, 2025
pulisher
Jun 06, 2025

Recursion Pharmaceuticals shares surge on AI model release By Investing.com - Investing.com South Africa

Jun 06, 2025
pulisher
Jun 06, 2025

Recursion Pharmaceuticals shares surge on AI model release - Investing.com

Jun 06, 2025
pulisher
Jun 06, 2025

Recursion Pharmaceuticals call volume above normal and directionally bullish - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

Recursion Pharmaceuticals (RXRX) Sees Surge in Bullish Options Activity | RXRX Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Recursion (RXRX) Shares Jump on New Biomolecular Model Launch - GuruFocus

Jun 06, 2025

Recursion Pharmaceuticals Inc Azioni (RXRX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Capitalizzazione:     |  Volume (24 ore):